These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 19079988)

  • 1. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on P16, hMLH1 and MGMT genes and DNA methylation in human gastric cancer cells].
    Meng CF; Zhu XJ; Dai DQ; Peng G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):494-7. PubMed ID: 19742343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reversal effect of 5-Aza-dc on cisplatin-resistance in human NSCLC cells in vitro].
    Wu F; Hu CH
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):349-53. PubMed ID: 21875463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells.
    Meng CF; Su B; Li W
    Mol Med Rep; 2011; 4(6):1273-8. PubMed ID: 21850374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
    Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
    Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
    Arnold CN; Goel A; Boland CR
    Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histone H3 lysine 9 methylation is associated with the expression of hMLH1 and DNA methylation in gastric cancer cells].
    Meng CF; Zhu XJ; Peng G
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2490-3. PubMed ID: 19080631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer.
    Zhang YW; Zheng Y; Wang JZ; Lu XX; Wang Z; Chen LB; Guan XX; Tong JD
    Epigenetics; 2014 Jun; 9(6):896-909. PubMed ID: 24699858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro study of human mutL homolog 1 hypermethylation in inducing drug resistance of esophageal carcinoma.
    Cao Y; Chen Y; Huang Y; Liu Z; Li G
    Ir J Med Sci; 2017 May; 186(2):257-263. PubMed ID: 26782688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.
    Meng CF; Zhu XJ; Peng G; Dai DQ
    World J Gastroenterol; 2007 Dec; 13(46):6166-71. PubMed ID: 18069755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
    Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
    Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
    Li Z; Zhang H; Yang J; Hao T; Li S
    Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
    Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
    J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of RASSF1A expression and promoter demethylation in Hep-2 cell line].
    Yang J; Ji W; Qu Y; He L; Zhao X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Jan; 25(2):64-6. PubMed ID: 21473137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
    Bai T; Tanaka T; Yukawa K; Umesaki N
    Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
    Meng CF; Zhu XJ; Peng G; Dai DQ
    Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
    Mossman D; Kim KT; Scott RJ
    BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of 5-Aza-2'-deoxycitydine and trichostatin A on expression and methylation of CHFR in human laryngreal carcinoma cell line].
    He L; Ji W; Yang J; Zhao X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 May; 26(9):418-21. PubMed ID: 22803411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.